Prediction of Therapeutic Effect to Treatment in Patients with Colorectal Liver Metastases Using Functional Magnetic Resonance Imaging and RECIST Criteria: A Pilot Study in Comparison between Bevacizumab-Containing Chemotherapy and Standard Chemotherapy
Background Response Evaluation Criteria in Solid Tumors (RECIST) criteria are widely used for evaluating the therapeutic effect of colorectal liver metastases (CRLM) patients, but showed undesirable accuracy. Objective This study aimed to evaluate the value of functional MRI compared with RECIST cri...
Gespeichert in:
| Veröffentlicht in: | Annals of surgical oncology 2022-06, Vol.29 (6), p.3938-3949 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 3949 |
|---|---|
| container_issue | 6 |
| container_start_page | 3938 |
| container_title | Annals of surgical oncology |
| container_volume | 29 |
| creator | Zhu, Hai-bin Xu, Da Zhang, Xiao-Yan Li, Xiao-Ting Xing, Bao-Cai Sun, Ying-Shi |
| description | Background
Response Evaluation Criteria in Solid Tumors (RECIST) criteria are widely used for evaluating the therapeutic effect of colorectal liver metastases (CRLM) patients, but showed undesirable accuracy.
Objective
This study aimed to evaluate the value of functional MRI compared with RECIST criteria in predicting the therapeutic effect in CRLM patients receiving neoadjuvant chemotherapy with and without bevacizumab.
Methods
Overall, 137 patients with CRLM who received neoadjuvant chemotherapy followed by hepatic resection between January 2013 and November 2018 were included and were divided into the bevacizumab and non-bevacizumab groups. Apparent diffusion coefficient (ADC) values of pre- and post-treatment diffusion-weighted imaging (DWI) were generated on the whole-volume (ADC
mean
), periphery (ADC
peri
), and isocenter (ADC
central
) of the tumor at the maximum slice. Overall survival (OS) and relapse-free survival (RFS) were used as prognostic indicators.
Results
Post-treatment ADC
mean
was significantly associated with OS (
p
= 0.001) and RFS (
p
= 0.008) in the bevacizumab group, while RECIST-defined response was found to be only significantly associated with RFS in the non-bevacizumab group (
p
= 0.042). When categorizing the bevacizumab group by the post-treatment ADC
mean
cut-off value of 1.15 ×10
-3
mm
2
/s, patients in the ADC response group showed significantly better OS than the non-response group (3-year OS: 91.5% vs. 64.5%,
p
= 0.001). However, no significant difference was found between RECIST-defined response and non-response in either OS (3-year OS: 60.2% vs. 44.0%,
p
= 0.104) or RFS (3-year RFS: 26.2% vs. 17.4%,
p
= 0.129) in the bevacizumab group.
Conclusions
DWI-related parameters such as post-treatment ADC
mean
could accurately reflect the therapeutic effectiveness and predicting survival in patients treated with bevacizumab, which is superior to the RECIST criteria. |
| doi_str_mv | 10.1245/s10434-021-11101-y |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2618904946</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2659820468</sourcerecordid><originalsourceid>FETCH-LOGICAL-c305t-b775eb2de6ad18dbc1ca5221d084a400828bd416811cf35491b6fab2aa3dffd63</originalsourceid><addsrcrecordid>eNp9klFv0zAQxyMEYmPwBXhAlnjhJWA7TprwNqIOKnWiWrvn6GJfWk-JXWxnU_nuSDjtAMEDkmWfzr_7n3z-J8lrRt8zLvIPnlGRiZRyljLGKEsPT5JzlseUKEr2NMa0KNOKF_lZ8sL7O0rZLKP58-QsyynLynx2nvxYOVRaBm0NsR3Z7NDBHsegJZl3HcpAgiUbhxAGNIFoQ1YQdAw9edBhR2rbWxcx6MlS36Mj1xjAx4We3HpttuRqNEf5SFzD1uAkfYM-JoxEshhgO1FgFLmZ14v1htROB3QaPpJLstK9DWQdRnWYetd22IPTsZi0GB4QDfmE9yD193GANq2tCaDNpFfvcLDh-JrDUXwd4g5O_XXzMnnWQe_x1eN5kdxezTf1l3T59fOivlymMs4rpO1slmPLFRagWKlaySTknDNFSwGC0pKXrRIsDp3JLstFxdqig5YDZKrrVJFdJO9Ountnv43oQzNoL7HvwaAdfcMLVlZUVGJC3_6D3tnRxelNVF6VnMbPjRQ_UdJZ7x12zd7pAdyhYbSZzNGczNFEczRHczSHWPTmUXpsB1S_S365IQLZCfDxymzR_en9H9mfpwbLQA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2659820468</pqid></control><display><type>article</type><title>Prediction of Therapeutic Effect to Treatment in Patients with Colorectal Liver Metastases Using Functional Magnetic Resonance Imaging and RECIST Criteria: A Pilot Study in Comparison between Bevacizumab-Containing Chemotherapy and Standard Chemotherapy</title><source>SpringerLink Journals</source><creator>Zhu, Hai-bin ; Xu, Da ; Zhang, Xiao-Yan ; Li, Xiao-Ting ; Xing, Bao-Cai ; Sun, Ying-Shi</creator><creatorcontrib>Zhu, Hai-bin ; Xu, Da ; Zhang, Xiao-Yan ; Li, Xiao-Ting ; Xing, Bao-Cai ; Sun, Ying-Shi</creatorcontrib><description>Background
Response Evaluation Criteria in Solid Tumors (RECIST) criteria are widely used for evaluating the therapeutic effect of colorectal liver metastases (CRLM) patients, but showed undesirable accuracy.
Objective
This study aimed to evaluate the value of functional MRI compared with RECIST criteria in predicting the therapeutic effect in CRLM patients receiving neoadjuvant chemotherapy with and without bevacizumab.
Methods
Overall, 137 patients with CRLM who received neoadjuvant chemotherapy followed by hepatic resection between January 2013 and November 2018 were included and were divided into the bevacizumab and non-bevacizumab groups. Apparent diffusion coefficient (ADC) values of pre- and post-treatment diffusion-weighted imaging (DWI) were generated on the whole-volume (ADC
mean
), periphery (ADC
peri
), and isocenter (ADC
central
) of the tumor at the maximum slice. Overall survival (OS) and relapse-free survival (RFS) were used as prognostic indicators.
Results
Post-treatment ADC
mean
was significantly associated with OS (
p
= 0.001) and RFS (
p
= 0.008) in the bevacizumab group, while RECIST-defined response was found to be only significantly associated with RFS in the non-bevacizumab group (
p
= 0.042). When categorizing the bevacizumab group by the post-treatment ADC
mean
cut-off value of 1.15 ×10
-3
mm
2
/s, patients in the ADC response group showed significantly better OS than the non-response group (3-year OS: 91.5% vs. 64.5%,
p
= 0.001). However, no significant difference was found between RECIST-defined response and non-response in either OS (3-year OS: 60.2% vs. 44.0%,
p
= 0.104) or RFS (3-year RFS: 26.2% vs. 17.4%,
p
= 0.129) in the bevacizumab group.
Conclusions
DWI-related parameters such as post-treatment ADC
mean
could accurately reflect the therapeutic effectiveness and predicting survival in patients treated with bevacizumab, which is superior to the RECIST criteria.</description><identifier>ISSN: 1068-9265</identifier><identifier>EISSN: 1534-4681</identifier><identifier>DOI: 10.1245/s10434-021-11101-y</identifier><identifier>PMID: 35013857</identifier><language>eng</language><publisher>Cham: Springer International Publishing</publisher><subject>Bevacizumab ; Chemotherapy ; Diffusion coefficient ; Functional magnetic resonance imaging ; Hepatobiliary Tumors ; Liver ; Medical prognosis ; Medicine ; Medicine & Public Health ; Metastases ; Metastasis ; Monoclonal antibodies ; Oncology ; Patients ; Solid tumors ; Surgery ; Surgical Oncology ; Survival ; Targeted cancer therapy</subject><ispartof>Annals of surgical oncology, 2022-06, Vol.29 (6), p.3938-3949</ispartof><rights>Society of Surgical Oncology 2021</rights><rights>2021. Society of Surgical Oncology.</rights><rights>Society of Surgical Oncology 2021.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c305t-b775eb2de6ad18dbc1ca5221d084a400828bd416811cf35491b6fab2aa3dffd63</citedby><cites>FETCH-LOGICAL-c305t-b775eb2de6ad18dbc1ca5221d084a400828bd416811cf35491b6fab2aa3dffd63</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1245/s10434-021-11101-y$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1245/s10434-021-11101-y$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27924,27925,41488,42557,51319</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35013857$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Zhu, Hai-bin</creatorcontrib><creatorcontrib>Xu, Da</creatorcontrib><creatorcontrib>Zhang, Xiao-Yan</creatorcontrib><creatorcontrib>Li, Xiao-Ting</creatorcontrib><creatorcontrib>Xing, Bao-Cai</creatorcontrib><creatorcontrib>Sun, Ying-Shi</creatorcontrib><title>Prediction of Therapeutic Effect to Treatment in Patients with Colorectal Liver Metastases Using Functional Magnetic Resonance Imaging and RECIST Criteria: A Pilot Study in Comparison between Bevacizumab-Containing Chemotherapy and Standard Chemotherapy</title><title>Annals of surgical oncology</title><addtitle>Ann Surg Oncol</addtitle><addtitle>Ann Surg Oncol</addtitle><description>Background
Response Evaluation Criteria in Solid Tumors (RECIST) criteria are widely used for evaluating the therapeutic effect of colorectal liver metastases (CRLM) patients, but showed undesirable accuracy.
Objective
This study aimed to evaluate the value of functional MRI compared with RECIST criteria in predicting the therapeutic effect in CRLM patients receiving neoadjuvant chemotherapy with and without bevacizumab.
Methods
Overall, 137 patients with CRLM who received neoadjuvant chemotherapy followed by hepatic resection between January 2013 and November 2018 were included and were divided into the bevacizumab and non-bevacizumab groups. Apparent diffusion coefficient (ADC) values of pre- and post-treatment diffusion-weighted imaging (DWI) were generated on the whole-volume (ADC
mean
), periphery (ADC
peri
), and isocenter (ADC
central
) of the tumor at the maximum slice. Overall survival (OS) and relapse-free survival (RFS) were used as prognostic indicators.
Results
Post-treatment ADC
mean
was significantly associated with OS (
p
= 0.001) and RFS (
p
= 0.008) in the bevacizumab group, while RECIST-defined response was found to be only significantly associated with RFS in the non-bevacizumab group (
p
= 0.042). When categorizing the bevacizumab group by the post-treatment ADC
mean
cut-off value of 1.15 ×10
-3
mm
2
/s, patients in the ADC response group showed significantly better OS than the non-response group (3-year OS: 91.5% vs. 64.5%,
p
= 0.001). However, no significant difference was found between RECIST-defined response and non-response in either OS (3-year OS: 60.2% vs. 44.0%,
p
= 0.104) or RFS (3-year RFS: 26.2% vs. 17.4%,
p
= 0.129) in the bevacizumab group.
Conclusions
DWI-related parameters such as post-treatment ADC
mean
could accurately reflect the therapeutic effectiveness and predicting survival in patients treated with bevacizumab, which is superior to the RECIST criteria.</description><subject>Bevacizumab</subject><subject>Chemotherapy</subject><subject>Diffusion coefficient</subject><subject>Functional magnetic resonance imaging</subject><subject>Hepatobiliary Tumors</subject><subject>Liver</subject><subject>Medical prognosis</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Metastases</subject><subject>Metastasis</subject><subject>Monoclonal antibodies</subject><subject>Oncology</subject><subject>Patients</subject><subject>Solid tumors</subject><subject>Surgery</subject><subject>Surgical Oncology</subject><subject>Survival</subject><subject>Targeted cancer therapy</subject><issn>1068-9265</issn><issn>1534-4681</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp9klFv0zAQxyMEYmPwBXhAlnjhJWA7TprwNqIOKnWiWrvn6GJfWk-JXWxnU_nuSDjtAMEDkmWfzr_7n3z-J8lrRt8zLvIPnlGRiZRyljLGKEsPT5JzlseUKEr2NMa0KNOKF_lZ8sL7O0rZLKP58-QsyynLynx2nvxYOVRaBm0NsR3Z7NDBHsegJZl3HcpAgiUbhxAGNIFoQ1YQdAw9edBhR2rbWxcx6MlS36Mj1xjAx4We3HpttuRqNEf5SFzD1uAkfYM-JoxEshhgO1FgFLmZ14v1htROB3QaPpJLstK9DWQdRnWYetd22IPTsZi0GB4QDfmE9yD193GANq2tCaDNpFfvcLDh-JrDUXwd4g5O_XXzMnnWQe_x1eN5kdxezTf1l3T59fOivlymMs4rpO1slmPLFRagWKlaySTknDNFSwGC0pKXrRIsDp3JLstFxdqig5YDZKrrVJFdJO9Ountnv43oQzNoL7HvwaAdfcMLVlZUVGJC3_6D3tnRxelNVF6VnMbPjRQ_UdJZ7x12zd7pAdyhYbSZzNGczNFEczRHczSHWPTmUXpsB1S_S365IQLZCfDxymzR_en9H9mfpwbLQA</recordid><startdate>202206</startdate><enddate>202206</enddate><creator>Zhu, Hai-bin</creator><creator>Xu, Da</creator><creator>Zhang, Xiao-Yan</creator><creator>Li, Xiao-Ting</creator><creator>Xing, Bao-Cai</creator><creator>Sun, Ying-Shi</creator><general>Springer International Publishing</general><general>Springer Nature B.V</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>202206</creationdate><title>Prediction of Therapeutic Effect to Treatment in Patients with Colorectal Liver Metastases Using Functional Magnetic Resonance Imaging and RECIST Criteria: A Pilot Study in Comparison between Bevacizumab-Containing Chemotherapy and Standard Chemotherapy</title><author>Zhu, Hai-bin ; Xu, Da ; Zhang, Xiao-Yan ; Li, Xiao-Ting ; Xing, Bao-Cai ; Sun, Ying-Shi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c305t-b775eb2de6ad18dbc1ca5221d084a400828bd416811cf35491b6fab2aa3dffd63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Bevacizumab</topic><topic>Chemotherapy</topic><topic>Diffusion coefficient</topic><topic>Functional magnetic resonance imaging</topic><topic>Hepatobiliary Tumors</topic><topic>Liver</topic><topic>Medical prognosis</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Metastases</topic><topic>Metastasis</topic><topic>Monoclonal antibodies</topic><topic>Oncology</topic><topic>Patients</topic><topic>Solid tumors</topic><topic>Surgery</topic><topic>Surgical Oncology</topic><topic>Survival</topic><topic>Targeted cancer therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Zhu, Hai-bin</creatorcontrib><creatorcontrib>Xu, Da</creatorcontrib><creatorcontrib>Zhang, Xiao-Yan</creatorcontrib><creatorcontrib>Li, Xiao-Ting</creatorcontrib><creatorcontrib>Xing, Bao-Cai</creatorcontrib><creatorcontrib>Sun, Ying-Shi</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Annals of surgical oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zhu, Hai-bin</au><au>Xu, Da</au><au>Zhang, Xiao-Yan</au><au>Li, Xiao-Ting</au><au>Xing, Bao-Cai</au><au>Sun, Ying-Shi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prediction of Therapeutic Effect to Treatment in Patients with Colorectal Liver Metastases Using Functional Magnetic Resonance Imaging and RECIST Criteria: A Pilot Study in Comparison between Bevacizumab-Containing Chemotherapy and Standard Chemotherapy</atitle><jtitle>Annals of surgical oncology</jtitle><stitle>Ann Surg Oncol</stitle><addtitle>Ann Surg Oncol</addtitle><date>2022-06</date><risdate>2022</risdate><volume>29</volume><issue>6</issue><spage>3938</spage><epage>3949</epage><pages>3938-3949</pages><issn>1068-9265</issn><eissn>1534-4681</eissn><abstract>Background
Response Evaluation Criteria in Solid Tumors (RECIST) criteria are widely used for evaluating the therapeutic effect of colorectal liver metastases (CRLM) patients, but showed undesirable accuracy.
Objective
This study aimed to evaluate the value of functional MRI compared with RECIST criteria in predicting the therapeutic effect in CRLM patients receiving neoadjuvant chemotherapy with and without bevacizumab.
Methods
Overall, 137 patients with CRLM who received neoadjuvant chemotherapy followed by hepatic resection between January 2013 and November 2018 were included and were divided into the bevacizumab and non-bevacizumab groups. Apparent diffusion coefficient (ADC) values of pre- and post-treatment diffusion-weighted imaging (DWI) were generated on the whole-volume (ADC
mean
), periphery (ADC
peri
), and isocenter (ADC
central
) of the tumor at the maximum slice. Overall survival (OS) and relapse-free survival (RFS) were used as prognostic indicators.
Results
Post-treatment ADC
mean
was significantly associated with OS (
p
= 0.001) and RFS (
p
= 0.008) in the bevacizumab group, while RECIST-defined response was found to be only significantly associated with RFS in the non-bevacizumab group (
p
= 0.042). When categorizing the bevacizumab group by the post-treatment ADC
mean
cut-off value of 1.15 ×10
-3
mm
2
/s, patients in the ADC response group showed significantly better OS than the non-response group (3-year OS: 91.5% vs. 64.5%,
p
= 0.001). However, no significant difference was found between RECIST-defined response and non-response in either OS (3-year OS: 60.2% vs. 44.0%,
p
= 0.104) or RFS (3-year RFS: 26.2% vs. 17.4%,
p
= 0.129) in the bevacizumab group.
Conclusions
DWI-related parameters such as post-treatment ADC
mean
could accurately reflect the therapeutic effectiveness and predicting survival in patients treated with bevacizumab, which is superior to the RECIST criteria.</abstract><cop>Cham</cop><pub>Springer International Publishing</pub><pmid>35013857</pmid><doi>10.1245/s10434-021-11101-y</doi><tpages>12</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1068-9265 |
| ispartof | Annals of surgical oncology, 2022-06, Vol.29 (6), p.3938-3949 |
| issn | 1068-9265 1534-4681 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2618904946 |
| source | SpringerLink Journals |
| subjects | Bevacizumab Chemotherapy Diffusion coefficient Functional magnetic resonance imaging Hepatobiliary Tumors Liver Medical prognosis Medicine Medicine & Public Health Metastases Metastasis Monoclonal antibodies Oncology Patients Solid tumors Surgery Surgical Oncology Survival Targeted cancer therapy |
| title | Prediction of Therapeutic Effect to Treatment in Patients with Colorectal Liver Metastases Using Functional Magnetic Resonance Imaging and RECIST Criteria: A Pilot Study in Comparison between Bevacizumab-Containing Chemotherapy and Standard Chemotherapy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T10%3A04%3A40IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prediction%20of%20Therapeutic%20Effect%20to%20Treatment%20in%20Patients%20with%20Colorectal%20Liver%20Metastases%20Using%20Functional%20Magnetic%20Resonance%20Imaging%20and%20RECIST%20Criteria:%20A%20Pilot%20Study%20in%20Comparison%20between%20Bevacizumab-Containing%20Chemotherapy%20and%20Standard%20Chemotherapy&rft.jtitle=Annals%20of%20surgical%20oncology&rft.au=Zhu,%20Hai-bin&rft.date=2022-06&rft.volume=29&rft.issue=6&rft.spage=3938&rft.epage=3949&rft.pages=3938-3949&rft.issn=1068-9265&rft.eissn=1534-4681&rft_id=info:doi/10.1245/s10434-021-11101-y&rft_dat=%3Cproquest_cross%3E2659820468%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2659820468&rft_id=info:pmid/35013857&rfr_iscdi=true |